Literature DB >> 3080008

Necessity of antibody response in the treatment of African trypanosomiasis with alpha-difluoromethylornithine.

A J Bitonti, P P McCann, A Sjoerdsma.   

Abstract

The role of the immune system in the clearance of Trypanosoma brucei brucei from the bloodstream during alpha-difluoromethylornithine (DFMO) treatment was studied by determining the effects of dexamethasone on immune and therapeutic responses in rats infected with T.b. brucei. Normal DFMO-treated animals exhibited strong antibody responses to trypanosomes and were cured of T. b. brucei infection by a 7-day regimen of 2% DFMO in drinking water. Animals pretreated with dexamethasone were not cured by the same level of DFMO treatment. Nonetheless, in rats pretreated with dexamethasone, trypanosomes were cleared from blood during treatment with DFMO, but all immunocompromised animals eventually succumbed to relapses of the infection. Athymic (nude) mice were cured of T. b. brucei infection by a 72-hr course of treatment with 2% DFMO in their drinking water. These findings suggest that relatively low levels of T-cell-independent, antitrypanosomal antibodies are adequate to clear the bloodstream of parasites during DFMO therapy but that an intact immune response is necessary for cures of the disease to be obtained.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3080008     DOI: 10.1016/0006-2952(86)90534-4

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  10 in total

1.  Impairment of macrophage function by inhibitors of ornithine decarboxylase activity.

Authors:  F Kierszenbaum; J J Wirth; P P McCann; A Sjoerdsma
Journal:  Infect Immun       Date:  1987-10       Impact factor: 3.441

2.  Differential susceptibility to DL-alpha-difluoromethylornithine in clinical isolates of Trypanosoma brucei rhodesiense.

Authors:  C J Bacchi; H C Nathan; T Livingston; G Valladares; M Saric; P D Sayer; A R Njogu; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

3.  Anti-schistosome chemotherapy enhanced by antibodies specific for a parasite esterase.

Authors:  M J Doenhoff; J Modha; J R Lambertucci
Journal:  Immunology       Date:  1988-12       Impact factor: 7.397

Review 4.  Eflornithine. A new drug in the treatment of sleeping sickness.

Authors:  I Van Bogaert; A Haemers
Journal:  Pharm Weekbl Sci       Date:  1989-06-23

Review 5.  Human African trypanosomiasis: pharmacological re-engagement with a neglected disease.

Authors:  M P Barrett; D W Boykin; R Brun; R R Tidwell
Journal:  Br J Pharmacol       Date:  2007-07-09       Impact factor: 8.739

6.  Cure of Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense infections in mice with an irreversible inhibitor of S-adenosylmethionine decarboxylase.

Authors:  A J Bitonti; T L Byers; T L Bush; P J Casara; C J Bacchi; A B Clarkson; P P McCann; A Sjoerdsma
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

7.  Effects of alpha-difluoromethylornithine on protein synthesis and synthesis of the variant-specific glycoprotein (VSG) in Trypanosoma brucei brucei.

Authors:  A J Bitonti; D E Cross-Doersen; P P McCann
Journal:  Biochem J       Date:  1988-02-15       Impact factor: 3.857

8.  In vivo effect of Commiphora swynnertonii ethanolic extracts on Trypanosoma congolense and selected immunological components in mice.

Authors:  Yakob P Nagagi; Richard S Silayo; Claudius Luziga; Eliningaya J Kweka
Journal:  BMC Complement Altern Med       Date:  2017-05-23       Impact factor: 3.659

9.  Chemotherapy of human african trypanosomiasis.

Authors:  Cyrus J Bacchi
Journal:  Interdiscip Perspect Infect Dis       Date:  2009-08-20

10.  Untargeted metabolomics reveals a lack of synergy between nifurtimox and eflornithine against Trypanosoma brucei.

Authors:  Isabel M Vincent; Darren J Creek; Karl Burgess; Debra J Woods; Richard J S Burchmore; Michael P Barrett
Journal:  PLoS Negl Trop Dis       Date:  2012-05-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.